Why the study?
To evaluate the effectiveness and safety of andexanet compared with prothrombin complex concentrates in patients with intracranial hemorrhage associated with apixaban or rivaroxaban.
Does andexanet improve hemostasis compared to prothrombin complex concentrates in patients with apixaban or rivaroxaban-related intracranial hemorrhage?
Does andexanet improve hemostasis compared to prothrombin complex concentrates in patients with apixaban or rivaroxaban-related intracranial hemorrhage?
In patients with factor Xa inhibitor-related intracranial hemorrhage, andexanet improved hemostatic efficacy compared to PCCs but was associated with a higher risk of thrombotic events during the hospital stay.
Should not yet change reversal practice; leaves open the net clinical benefit of andexanet versus PCC in FXa-inhibitor ICrH.
No takes yet. Share an insight, caveat, or question.
Panos et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: